Marshall Wace
SPRB

Marshall Wace’s Spruce Biosciences SPRB Stock Holding History

Marshall Wace’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-963
Closed -$57.1K – 3062
2024
Q1 		$57.1K Sell
963
-447
-32% -$114K ﹤0.01% 2338
2023
Q4 		$310K Buy
+1,410
New +$163K ﹤0.01% 1880
2021
Q1 		– Sell
-185
Closed -$337K – 2931
2020
Q4 		$337K Buy
+185
New +$307K ﹤0.01% 1619

Other funds holding SPRB

RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return

Marshall Wace's SPRB Position: Q2 2024 in Review

Marshall Wace sold out of Spruce Biosciences (SPRB) in Q2 2024, closing a stake of 963 shares — an estimated $57.1K sold.

Marshall Wace first reported a position in SPRB in Q4 2020 and held it in 3 quarters. The position peaked at $337K in Q4 2020. 37 funds tracked by Wall St. Rank hold SPRB as of Q2 2024.

  • Marshall Wace reported no remaining Spruce Biosciences position as of Q2 2024 after selling out during the quarter.
  • Marshall Wace sold 963 Spruce Biosciences shares in Q2 2024, an estimated $57.1K.
  • Marshall Wace first reported a position in Spruce Biosciences in Q4 2020 and held it in 3 quarters.
  • Marshall Wace's Spruce Biosciences position peaked at $337K in Q4 2020.
  • 37 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2024.

Based on Marshall Wace's 13F filing for Q2 2024, filed 14 Aug 2024.